神経発達障害のない一般的なと関連したATP2B1の変種と,その基礎となるメカニズム
PubMedで要約を見る
まとめ
この要約は機械生成です。ATP2B1遺伝子は一般的なと関連しています. ATP2B1の特定の変異はを引き起こすことができ,より深刻な変異は神経発達障害に関連しており,現象的違いを説明します.
科学分野
- 遺伝学
- 神経科学
- 分子生物学
背景
- ATP2B1遺伝子は,脳カルシウムホメオスタシスに不可欠な血清膜カルシウム輸送ATPase 1 (PMCA1) をコードする.
- ATP2B1の変種は神経発達障害に関与しているが,におけるその役割は不明である.
研究 の 目的
- ATP2B1変種ととの関連を調査する.
- ATP2B1に関連する疾患における遺伝子型-フェノタイプの相関性とフェノタイプの異質性を理解する.
主な方法
- エピレプシー患者のコホートにおけるトリオベースの全エクソームシーケンシング (WES).
- ATP2B1変異の病原性,ゲノタイプ-フェノタイプ相関性,および時空表現パターンの分析.
主要な成果
- ATP2B1の変種は,一般性症または発熱性症の遺伝性症を有する5人の患者で確認された.
- ATP2B1のデノボと共分泌されたミッセンセの変異は,タンパク質の安定性を損なうことが判明しました.
- 神経発達障害に関連した変種と比較して,に関連した変種はより有害な効果を示しました.
結論
- ATP2B1は一般的なの潜在的な候補遺伝子です.
- 遺伝子発現パターンと変異性の重さは,ATP2B1に関連する神経学的状態の現象スペクトルを説明する.
関連する概念動画
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Focal aware seizures: In these seizures, the person remains conscious...
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
ATP synthase or ATPase is among the most conserved proteins found in bacteria, mammals, and plants. This enzyme can catalyze a forward reaction in response to the electrochemical gradient, producing ATP from ADP and inorganic phosphate. ATP synthase can also work in a reverse direction by hydrolyzing ATP and generating an electrochemical gradient. Different forms of ATP synthases have evolved special features to meet the specific demands of the cell. Based on their specific feature, ATP...

